-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (i.e., Alzheimer's disease) is a degenerative lesions of the central nervous system that occurs in early and early age, mainly characterized by cognitive decline and behavioral impairment, such as inability to eat autonomously, memory disorders or complete relics, and are also accompanied in part by aphasia and visual impairment.
, the number of People with Alzheimer's disease in China is expected to exceed 10 million, with an average of 3.5 out of every 1,000 people, and that proportion is likely to continue to increase as the aging of the Chinese population progresses.
the current drug treatment for Alzheimer's disease is mainly on the treatment of the disease, and there are not many drugs available to delay or prevent progression.
November 2, 2019, the National Drug Administration approved a listing application for the original new drug for Alzheimer's disease, "Phase 9 One" (Glynette Sodium, code name: GV-971), "for mild to moderate Alzheimer's disease and to improve patients' cognitive function."
the development of this new AD drug is thought to be a different way, disruptive to reveal a new mechanism of anti-AD pathogenesis targeting the brain intestine axis. the emergence of
"GV-971 provides a direction and means to promote basic research.
" neuroscientist zhang Xu, a member of the Chinese Academy of Sciences, said it may be the main pathway for neurodegenerative diseases, and the implication is that the metabolic system and the immune system can influence the brain through the action of the brain's intestinal axis.
Phase 9 Phase 1" improves cognitive decline by reshaping the balance of intestinal flora, inhibiting the abnormal increase of specific metabolites of intestinal flora, reducing peripheral and central inflammation, and reducing beta amyloid protein deposition and Tau protein overphosation.
as the first anti-AD drug in China to conduct a large-scale phase III clinical trial, and the first new drug for the treatment of Alzheimer's disease in the world. the advent of the
Phase 1 of the ninth issue has brought new hope to countless people with Alzheimer's disease and their families.
.